Primary Central Nervous System Lymphoma | Norton Healthcare

Indication: Primary Central Nervous System Lymphoma

An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)

Sub-indication: Hematological Malignancies

Study Type: Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Sponsor: ONO Pharmaceutical Co., Ltd.

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.